A New Target for Anti-aging Interventions?
New research from a team at the Marshall University Joan C. Edwards School of Medicine demonstrates that the Na/K-ATPase oxidant amplification loop (NAKL) is intimately involved in the aging process and may serve as a target for anti-aging interventions. The researchers were also able to successfully demonstrate the therapeutic potential of pNaKtide, a synthetic peptide, in improving impaired physiological functions and disease development.
The findings are published in the June 26, 2018, edition of Scientific Reports, an online journal from the publishers of Nature.
"I am extremely excited about the research involved in the current Scientific Reports article," said Joseph I. Shapiro, M.D., senior author and dean of the Joan C. Edwards School of Medicine. "I believe that our team has not only implicated the NAKL discovered by our colleague, Dr. Zijian Xie, in the aging process but identified a novel therapeutic target as well as a specific pharmacological strategy to actually slow the aging process. Although it will be some time before we can test these concepts in human subjects, I am cautiously optimistic that clinical therapeutics will ultimately result. "
The team's extensive year-long study first focused on aging mice who were given a western diet to stimulate oxidant stress to antagonize the NAKL. The western diet increased the functional and structural evidence for aging; however, the introduction of pNaKtide slowed these changes in the mice. The same results were then replicated when human dermal fibroblasts were exposed to different types of oxidant stress in vitro by stimulating the NAKL, increasing expression of senescence markers, and causing cell injury. With pNaKtide treatment, the researchers demonstrated that the negative attributes associated with aging were significantly dampened.
"Our data clearly suggest that the Na/K-ATPase oxidant amplification loop is intimately involved in the aging process and, if confirmed in human studies, might ultimately serve as a therapeutic target," said first author Komal Sodhi, M.D., an associate professor of surgery and biomedical sciences at the Joan C. Edwards School of Medicine. "If the pNaKtide can be safely used in humans, it might be possible to study the applicability of that specific agent to the problem of clinical aging."
This article has been republished from materials provided by Marshall University. Note: material may have been edited for length and content. For further information, please contact the cited source.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.